Lupin receives Establishment Inspection Report from USFDA for its Aurangabad manufacturing facility

The inspection was conductedfrom March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification ofthe facility is Voluntary Action Indicated (VAI).

Global pharma  firm Lupin Limited (Lupin) on Tuesday announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The U.S. FDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

“We are pleased to receive the EIR with VAI status from the U.S. FDA as an outcome of the recent inspection of our Aurangabad facility. It is a testament to our commitment to consistently upholding the highest standards of compliance and providing high-quality healthcare solutions to patients worldwide,”said Nilesh Gupta, Managing Director, Lupin.

Meanwhile, in a regulatory filing, the company said that a meeting of the Board of Directors of the Company will be held on Monday, May 6, 2024, inter alia, to consider and take on record audited financial results of the Company for the quarter and year-ended March 31, 2024 and recommend dividend, if any.